Silver Spring, Maryland—(ENEWSPF)—February 12, 2014. The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for chronic lymphocytic leukemia (CLL) patients who have received at least one previous therapy.
FDA Approves Imbruvica to Treat Chronic Lymphocytic Leukemia
More in Health and Fitness:
